CLINICAL_TRIALS ClinicalTrials.gov record update

A Single-Arm, Prospective Phase II Clinical Study on the Neoadjuvant Tislelizumab -Cetuximab - TP(cisplatin and Albumin-paclitaxel) Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06728618
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:03.965039+00:00
Published At: 2024-12-11T00:00:00+00:00
Record Updated At: 2024-12-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Oral Squamous Cell Carcinoma (OSCC)", "Oropharyngeal Squamous Cell Carcinoma (SCC)", "Resectable Oral and Oropharyngeal Squamous Cell Carcinoma", "Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-12-11"
protocolSection.identificationModule.nctId: "NCT06728618"
protocolSection.identificationModule.officialTitle: "A Single-Arm, Prospective Phase II Clinical Study on the Neoadjuvant Tislelizumab -Cetuximab - TP(cisplatin and Albumin-paclitaxel) Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.